Publications

5674 Results

New challenges in endpoints for drug development in advanced melanoma [PMID22142824; PMC3422891]

Authors
A Ribas;P Hersey;MR Middleton;H Gogas;K Flaherty;V Sondak;JM Kirkwood
Journal / Conference
Clinical Cancer Research 18(2):336-341
Year
2012
Research Committee(s)
Melanoma
PMID
PMID22142824
PMC
PMC3422891

Strategies to increase efficiency in protocol development

Authors
K Stoermer
Journal / Conference
J Clin Oncol 30(suppl; abstr e16508); American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), publication only;
Year
2012
Research Committee(s)
Multiple sites and Outcomes and Comparative Effectiveness

Patterns of decision-making about cancer clinical trial participation among online cancer treatment community: a collaboration between SWOG and NexCura

Authors
JM Unger;D Hershman;D Burg;C Moinpour;K Albain;J Petersen;JJ Crowley
Journal / Conference
Journal of Clinical Oncology 30 (suppl; abstr CRA6009); American Society of Clinical Oncology 2012 Annual Mtg (June 1-5, 2012, Chicago, IL), oral presentation;
Year
2012
Research Committee(s)
Outcomes and Comparative Effectiveness

Older patient participation in SWOG lung cancer trials: Comparative analysis from 1993 to 2008.

Authors
PJ Hesketh;M Redman;J Unger;J Moon;D Gandara
Journal / Conference
J Clin Oncol 30 (suppl; abstr 7570); American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster presentation;
Year
2012
Research Committee(s)
Lung

Phase III trial of high dose interferon alpha- 2b versus cisplatin, vinblastine, DTIC plus IL2 and interferon in patients with high risk melanoma (SWOG S0008): an intergroup study of CALGB, COG, ECOG and SWOG.

Authors
L Flaherty;J Moon;M Atkins;R Tuthill;J Thompson;JT Vetto;FG Haluska;A Pappo;JA Sosman;B Redman;A Ribas;JM Kirkwood;V Sondak
Journal / Conference
J Clin Oncol 30 (suppl;abstr 8504); American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), oral presentation;
Year
2012
Research Committee(s)
Melanoma
Study Number(s)
S0008

CNS metastases as a site of progression on SWOG intergroup study S0008: a phase III trial of high dose interferon alpha-2b versus cisplatin, vinblastine, CTIC plus IL-2 and interferon in patients with high risk melanoma

Authors
W Samlowski;J Moon;M Witter;M Atkins;J Kirkwood;M Othus;A Ribas;V Sondak;L Flaherty
Journal / Conference
J Clin Oncol 30 (suppl; abstr 8527); American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster discussion;
Year
2012
Research Committee(s)
Melanoma
Study Number(s)
S0008

A phase III randomized intergroup trial (S0016) comparing CHOP + rituximab vs. CHOP + iodine-131-tositumomab for front-line treatment of follicular lymphoma: subset analyses and comparison of prognostic models

Authors
OW Press;J Unger;M Leblanc;L Rimsza;J Friedberg;M Czuczman;M Kaminski;RM Braziel;C Spier;DG Maloney;BD Cheson;TP Miller;RI Fisher
Journal / Conference
J Clin Oncol 30 (suppl; abstr 8001); American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), oral presentation;
Year
2012
Research Committee(s)
Lymphoma
Study Number(s)
S0016

SWOG 0421: Prognostic and predictive value of bone metabolism biomarkers (BMB) in castration resistant prostate cancer (CRPC) patients (pts) with skeletal metastases treated with docetaxel +/- atrasentan (ATR)

Authors
P Lara;B Ely;D Quinn;C Tangen;E Gertz;M Hussain;N Vogelzang;I Thompson;M Van Loan
Journal / Conference
J Clin Oncol 30 (suppl; abstr 4547); American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster discussion;
Year
2012
Research Committee(s)
Genitourinary
Study Number(s)
S0421

SWOG S0421: phase III study of docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer

Authors
DI Quinn;C Tangen;M Hussain;P Lara;A Goldkorn;MG Garzotto;PC Mack;M Carducci;JP Monk;P Twardowski;P Van Veldhuizen;N Agarwal;CS Higano;N Vogelzang;IM Thompson
Journal / Conference
J Clin Oncol 30 (suppl; abstr 4511); American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), oral presentation;
Year
2012
Research Committee(s)
Genitourinary
Study Number(s)
S0421

Results of circulating tumor cell counts using the CellSearch platform in a prospective randomized phase III SWOG-sponsored prostate cancer trial (S0421)

Authors
N Vogelzang;B Ely;LM Fink;A Goldkorn;C Tangen;P Twardowski;P Van Veldhuizen;N Agarwal;M Carducci;JP Monk;M Garzotto;PC Mack;PN Lara;C Higano;M Hussain;D Quinn;RJ Cote;IM Thompson
Journal / Conference
J Clin Oncol 30 (suppl; abstr 10503); American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), oral presentation;
Year
2012
Research Committee(s)
Genitourinary
Study Number(s)
S0421